Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lord

Showing results (251-260 of 594) with videos related to

Pageof 60
Sort By:
Trials|April 4, 2023
A cluster randomised, 16-week, parallel-group multicentre trial to compare the effectiveness of a digital school-based cognitive behavioural resilience/wellbeing-building intervention targeting emotional and behavioural problems in vulnerable Year 4 primary school children in whole classes, to the usual school curriculum: a study protocol to the "CUES for Schools" trialS Jolley, J Lord, D Plant, et al.
ANZ Journal of Surgery|April 19, 2021
Impact of ultrasound on inguinal hernia repair rates in Australia: a population-based analysisMichael L Williams, Alexander S E McCarthy, Sally J Lord, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Next-generation sequencing, should I use anti-HER2 therapy for <i>HER2</i>-amplified tumors off-label? Illustrating an extrapolation frameworkDoah Cho, Sarah J Lord, John Simes, et al.
The Medical Journal of Australia|July 16, 2015
Australian clinical trial activity and burden of disease: an analysis of registered trials in National Health Priority AreasJacquelyne Lam, Sarah J Lord, Kylie E Hunter, et al.
The Journal of Pathology. Clinical Research|October 3, 2019
Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCRSaira Khalique, Stephen J Pettitt, Ger Kelly, et al.
Health Policy and Planning|August 31, 2006
Costs and outcomes of tuberculosis control in the Russian Federation: retrospective cohort analysisR A Atun, Y Samyshkin, F Drobniewski, et al.
Nature Reviews. Clinical Oncology|February 15, 2012
The potential of exploiting DNA-repair defects for optimizing lung cancer treatmentSophie Postel-Vinay, Elsa Vanhecke, Ken A Olaussen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2021
Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reportingKatherine E Francis, Val Gebski, Sarah J Lord, et al.
Gut|January 7, 2016
The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysisOliver M Fisher, Sarah J Lord, Dan Falkenback, et al.
European Journal of Cancer (Oxford, England : 1990)|December 29, 2009
Historical cross-trial comparisons for competing treatments in advanced breast cancer--an empirical analysis of biasC K Lee, S J Lord, M R Stockler, et al.
Pageof 60

Showing results (251-260 of 594) with videos related to

Sort By:
Pageof 60
Trials|April 4, 2023
A cluster randomised, 16-week, parallel-group multicentre trial to compare the effectiveness of a digital school-based cognitive behavioural resilience/wellbeing-building intervention targeting emotional and behavioural problems in vulnerable Year 4 primary school children in whole classes, to the usual school curriculum: a study protocol to the "CUES for Schools" trialS Jolley, J Lord, D Plant, et al.
ANZ Journal of Surgery|April 19, 2021
Impact of ultrasound on inguinal hernia repair rates in Australia: a population-based analysisMichael L Williams, Alexander S E McCarthy, Sally J Lord, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Next-generation sequencing, should I use anti-HER2 therapy for <i>HER2</i>-amplified tumors off-label? Illustrating an extrapolation frameworkDoah Cho, Sarah J Lord, John Simes, et al.
The Medical Journal of Australia|July 16, 2015
Australian clinical trial activity and burden of disease: an analysis of registered trials in National Health Priority AreasJacquelyne Lam, Sarah J Lord, Kylie E Hunter, et al.
The Journal of Pathology. Clinical Research|October 3, 2019
Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCRSaira Khalique, Stephen J Pettitt, Ger Kelly, et al.
Health Policy and Planning|August 31, 2006
Costs and outcomes of tuberculosis control in the Russian Federation: retrospective cohort analysisR A Atun, Y Samyshkin, F Drobniewski, et al.
Nature Reviews. Clinical Oncology|February 15, 2012
The potential of exploiting DNA-repair defects for optimizing lung cancer treatmentSophie Postel-Vinay, Elsa Vanhecke, Ken A Olaussen, et al.
European Journal of Cancer (Oxford, England : 1990)|March 23, 2021
Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reportingKatherine E Francis, Val Gebski, Sarah J Lord, et al.
Gut|January 7, 2016
The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysisOliver M Fisher, Sarah J Lord, Dan Falkenback, et al.
European Journal of Cancer (Oxford, England : 1990)|December 29, 2009
Historical cross-trial comparisons for competing treatments in advanced breast cancer--an empirical analysis of biasC K Lee, S J Lord, M R Stockler, et al.
Pageof 60